San Francisco, CANCT05849662Now EnrollingIRB Ready

Juvenile Myelomonocytic Leukemia Clinical Trial in San Francisco, CA

Access cutting-edge juvenile myelomonocytic leukemia treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Therapeutic Advances in Childhood Leukemia Consortium

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions...

Expert Care in San Francisco

Access juvenile myelomonocytic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related juvenile myelomonocytic leukemia treatment provided free

Apply for This San Francisco Location

Check if you qualify for this juvenile myelomonocytic leukemia clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Juvenile Myelomonocytic Leukemia Study in San Francisco

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Who Can Participate

Inclusion Criteria

Age • Patients must be ≥ 1 month and ≤21 years of age at enrollment. Diagnosis • Patients must meet the 2022 International Consensus Classification criteria for JMML. The diagnosis is made based on the following criteria:. Clinical and hematologic features (the first 2 features are present in most cases; the last 2 are required):
Peripheral blood monocyte count ≥ 1 × 109/L\
Splenomegaly†
Blast percentage in PB and BM \< 20%
Absence of BCR::ABL1
This monocyte threshold is not reached in approximately 7% of cases. †Splenomegaly is absent in 3% of cases at presentation. II. Genetic studies (1 finding required):
Somatic mutation in PTPN11‡ or KRAS‡ or NRAS‡ or RRAS or RRAS2‡
Clinical diagnosis of neurofibromatosis type 1 or germline NF1 mutation and loss of heterozygosity of NF1 or somatic biallelic loss of NF1
Germline CBL mutation and loss of heterozygosity of CBL, or somatic mutation(s) in CBL§
Germline mutations (indicating Noonan syn

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT05849662) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Juvenile Myelomonocytic Leukemia Treatment Options in San Francisco, CA

If you're searching for juvenile myelomonocytic leukemia treatment options in San Francisco, CA, this clinical trial (NCT05849662) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced juvenile myelomonocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all juvenile myelomonocytic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in San Francisco, CA

See all leukemia clinical trials recruiting in San Francisco — not just this study.

Browse Leukemia Trials in San Francisco →

Browse More Trials by Condition

Leukemia TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA